Chronic HCV genotype 1a · F2 fibrosis on FibroScan · DAA pan-genotypic regimen 12 weeks → SVR12 achieved · HCC surveillance opened.
Aleksandar is in the elevated-risk band — F2 fibrosis from chronic HCV. Modern DAA therapy achieves SVR12 (cure) in >97%. Critical insight: SVR ≠ HCC immunity — fibrotic livers retain residual HCC risk for life and require continued biannual surveillance even after viral cure.
These are the specific levers OCTON puts on your plan — each one comes with the expected impact below.
Liver stiffness 8.4 kPa (METAVIR F2, significant fibrosis). CAP 232 dB/m (S1 mild steatosis). HCV RNA 1.2 × 10⁶ IU/mL, genotype 1a. Pre-treatment APRI 1.4, FIB-4 2.6 — both correlate with FibroScan F2.
Aleksandar's universal-cohort screen flipped his life. He thought a 1986 transfusion was old news; OCTON ran a single ELISA + RNA confirmation as part of his cubicle visit. Sofosbuvir/velpatasvir cured him in 12 weeks — but the more important catch was the F2 fibrosis. Post-cure, the system didn't 'discharge' him — it opened a lifetime biannual HCC surveillance lane. Five years later, SVR sustained, FibroScan dropped to F1, no HCC detected. The liver is the literal bridge between infectious diseases and oncology — OCTON treats it that way.
Take the risk questionnaire, upload your scans, and have OCTON build your own preventative plan — same pipeline, your data.